OUR STORY
Novigenix AI helps bring intelligent insights into the heterogeneity of patient response to cancer and its treatment for development of better therapeutics. AI combined with access to large sets of patient clinical and RNA data allows us to analyse patients’ immune profiles, and gain insights that can provide precise information, develop predictive capabilities, and tailor development of new therapies based on patient´s immune response to cancer.
Artificial Intelligence (AI) brings new possibilities to impact cancer patient outcomes. Over the past decade the Novigenix AI team has developed core competencies in development and measurement of RNA molecular biomarkers that are indicators of the presence or severity of a disease, in development of state-of-the-art data analytical models, and in regulatory approval of IVD products.
Novigenix AI analyses large amounts of RNA data from different patients’ blood to generate precise information about the patient response to cancer, the evolution of the cancer, and response to treatment. Novigenix AI solutions employ cutting edge molecular technologies ranging from NGS to RT-PCR based platforms, and they leverage the company’s proprietary Immuno-Transcriptomics LITOSeek™ platform which has been optimized and standardized for integrating patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to map the response of the immune system to onset and progression of disease.